GLP-1s and Alcohol in 2026: New Harvard-Led Study Finds Nearly Half of Drinkers Cut Back

Researchers from Harvard Medical School, McLean Hospital, Brown, Duke, Brandeis, and the RAND Corporation surveyed 2,009 U.S. adults through RAND's American Life Panel in March and April 2026. The work was funded by the National Institute on Alcohol Abuse and Alcoholism and published in JAMA Psychiatry in October 2026.

Of the adults surveyed, 368 were current or past GLP-1 users, and 242 of those were drinkers when they started the medication. Among those drinkers, 44.2% said they drank less after starting a GLP-1. Most of the rest reported no change, and only three people said they drank more.

One more number stands out: only about 10% of all respondents had ever heard that GLP-1s might reduce drinking. The effect patients keep describing in exam rooms and online forums is still news to most people.

The study used a standard NIH screening question — whether a person had, at any point in the past year, had four or more drinks on one occasion for women, or five or more for men — to flag drinking patterns that carry higher risk.

In that at-risk group, 54.1% reported drinking less after starting a GLP-1, 40.2% reported no change, and 5.7% (three individuals) reported drinking more. In other words, the people with the most room to benefit were also the most likely to cut back — a pattern that caught researchers' attention precisely because, until recently, the evidence for this effect was mostly anecdotal.

The study itself didn't test a biological mechanism, and the researchers are careful not to get ahead of the data. What exists so far is a consistent stream of patient reports: many people on GLP-1s describe quieter "food noise" — and some say the same quieting extends to alcohol cravings.

GLP-1 medications like semaglutide and tirzepatide slow gastric emptying and act on appetite-regulating pathways in the brain. Whether those same pathways dampen the rewarding effects of alcohol is exactly what randomized controlled trials now underway are designed to answer. Senior author Haiden Huskamp, a professor of health care policy at Harvard Medical School, expects more rigorous evidence within the next couple of years.

It's worth being clear about the limits, because they matter for anyone making treatment decisions:

• It measured perception, not quantity. Participants reported whether they drank less, more, or the same — not how much less.
• It was observational and self-reported. Co-author Alisa Busch of McLean Hospital noted the study wasn't designed to test whether GLP-1s work as a treatment for alcohol problems; that requires a randomized trial.
• Screening positive isn't a diagnosis. The heavy-drinking screen flags potentially unhealthy use, not alcohol use disorder, which is a clinical diagnosis.
• GLP-1s are not approved for alcohol use disorder. If drinking is a concern for you, proven treatments and medications already exist — and are widely underused. Talk to a licensed provider rather than self-treating with a weight loss drug.

For most patients, this study is encouraging context rather than a reason to change anything. If you're taking a GLP-1 for weight loss and find yourself drinking less, that's consistent with what nearly half of drinkers in this survey experienced — and drinking less is rarely a bad thing for weight, sleep, blood pressure, or liver health.

A few practical notes to discuss with your provider:

• Alcohol is calorie-dense and can work against your weight loss goals, so a reduced pull toward drinking may help your results.
• GLP-1s commonly cause nausea, vomiting, constipation, and diarrhea, especially during dose increases — and alcohol can make stomach upset worse. If nausea is an issue, anti-nausea support is available alongside treatment.
• Drinking on a slower-emptying stomach can hit differently than you're used to; many patients find their tolerance feels lower.
• GLP-1s aren't right for everyone. People with a personal or family history of medullary thyroid carcinoma or MEN 2, or a history of pancreatitis, need careful screening — which is why these medications should always be prescribed and monitored by a licensed provider.

If you're considering GLP-1 therapy for weight loss, JoeyMed makes the process straightforward. Complete a brief online health assessment, and a licensed provider will review your history, discuss whether treatment options like TIRZ HD are appropriate for you, and build a plan around your goals. Medications ship directly to your door, and your care team stays available for dose adjustments and side effect management along the way.

Explore your options at JoeyMed Weight Loss and see whether a medically supervised program is the right fit — for your weight, and maybe for your relationship with happy hour too.